Evaluation of effect of isoflavone on thyroid economy & autoimmunity in oophorectomised women: a randomised, double-blind, placebo-controlled trial

The potential of soy isoflavones to interfere with thyroid function has been reported. However, there are limited data regarding their effect on thyroid function and autoimmunity in surgical menopausal women. The present study aimed to evaluate the effect of isoflavones on thyroid function and autoi...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of medical research (New Delhi, India : 1994) India : 1994), 2011-06, Vol.133 (6), p.633-640
Main Authors: Mittal, Niti, Hota, Debasish, Dutta, Pinaki, Bhansali, Anil, Suri, Vanita, Aggarwal, Neelam, Marwah, R K, Chakrabarti, Amitava
Format: Article
Language:English
Subjects:
Autoimmunity
Autoimmunity - drug effects
Care and treatment
Dietary supplements
Double-Blind Method
Double-blind studies
Female
Glycine max - chemistry
Health aspects
Health risk assessment
Hormone replacement therapy
Humans
Isoflavones
Isoflavones - pharmacology
Menopause
Menopause - drug effects
Menopause - physiology
Original
Ovariectomy
Physiological aspects
Placebos
Studies
Thyroid gland
Thyroid Gland - drug effects
Thyroid Gland - metabolism
Thyroid Hormones - blood
Women
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The potential of soy isoflavones to interfere with thyroid function has been reported. However, there are limited data regarding their effect on thyroid function and autoimmunity in surgical menopausal women. The present study aimed to evaluate the effect of isoflavones on thyroid function and autoimmunity, menopausal symptoms, serum follicle stimulating hormone (FSH) and estradiol levels in oophorectomised women. A randomized, double blind, placebo-controlled trial was conducted in 43 oophorectomised women to evaluate the effect of soy isoflavones (75 mg/day for 12 wk) on serum thyroid profile (free T3, free T4, TSH, TBG and anti-TPO antibody titres) assessed at baseline, 6 and 12 wk after randomization. Assessment was also done for menopause symptom score (MSS) three weekly, and FSH and estradiol levels at baseline and at study completion. There was a significant alteration in free T3 levels in the group receiving isoflavones (4.05 ± 0.36, 4.12 ± 0.69 and 3.76 ± 0.55 pmol/l at baseline, 6 and 12 wk, respectively; P=0.02). However, the mean change in various thyroid parameters at 12 wk from baseline was not significantly different between the two groups. MSS was also significantly decreased at 9 and 12 wk from baseline with isoflavones (12.47 ± 8.15, 9.35 ± 5.23 and 9 ± 5.14 at baseline, 9 and 12 wk respectively; P=0.004) with significant improvement in urogenital symptoms compared to placebo. Isoflavones did not significantly affect other parameters during study period. There were no serious adverse events reported and the proportion of patients experiencing adverse events was similar between the two groups. Modest reduction in serum free T3 levels in the isoflavone group in the absence of any effect on other thyroid parameters might be considered clinically unimportant.
ISSN:0971-5916